Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BLK antisense RNA 1 (BLK-AS1) is a long noncoding RNA transcribed antisense to the BLK gene locus. As part of the lncRNA class, BLK-AS1 is implicated in the regulation of gene expression, potentially through cis- or trans-acting mechanisms, such as modulation of mRNA stability, chromatin structure, or epigenetic states[1][3][5]. Disease association studies link BLK-AS1 to systemic lupus erythematosus, suggesting a possible but as-yet-undefined regulatory role in immune cell biology or autoimmunity[3]. No direct therapeutic targeting of BLK-AS1 is established. As with other antisense RNAs, its dysregulation could contribute to disease through interference with gene expression, but research on its precise biological and disease functions remains limited.
Not applicable as a direct drug target. As a molecule, BLK-AS1 may function via RNA-RNA interactions, RNA-protein interactions, or epigenetic regulation (typical of antisense lncRNAs).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BLK antisense RNA 1 (BLK-AS1).